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It is obvious that interest in arrhythmia treatment is turning toward new devices and
ablation techniques, and it is, of course, certain that failed sinus or Tawara’s node should
be replaced by appropriate electronic pacemakers and that cardiac collapse by ventricular
ﬁbrillation or potentially lethal Torsades de Pointes should be stopped by electrical external
or implantable deﬁbrillators. For implanting pacemakers, only evidence of malfunction of
pacemaking and atrioventricular conduction is necessary. To install the deﬁbrillator, the
genetic preponderance of occurrence of these arrhythmias, or types of ventricular
arrhythmias likely to develop into fatal or other precipitating factors should be known.
Knowledge of pacemaking or precise mechanisms of generation of arrhythmias in cellular
and molecular levels is no longer necessary. Also for applying the ablation technique to
eliminate substrates of arrhythmia, only the proper area, automatic foci or a part or the
entire reentry circuit need to be known.
But how about pharmacological treatments? Is there no room for developing new
antiarrhythmic drugs? Drugs are relied on for atrial ﬁbrillation and prevention of sudden
cardiac death. For developing antiarrhythmic drugs, it has been required to know the precise
mechanisms of the generation of action potentials, those of diﬀerent forms of action
potentials, abnormalities of normal action potential which develop into arrhythmias etc.
Cardiac electrophysiology consists of complex, multifactorial phenomena simultaneously
occurring with channel or receptor related events. Molecular research aims to elucidate the
single function of the single molecule and how drugs act on ion channels, transporters or
extracellular or intracellular receptors, but how these drugs work on arrhythmias is only
known from experimental or clinical arrhythmias. We still need drugs to maintain sinus
rhythm after atrial deﬁbrillation, to stop the transition to ventricular ﬁbrillation, and drugs to
target pathophysiological alterations to prevent the occurrence of lethal arrhythmias. I have
been working using various arrhythmia models to test drugs. Classical antiarrhythmic drugs
acting on channels have both yin and yang eﬀects, but are still used, and probably no new
comers will emerge from these categories. However there is still a need for upstream acting
drugs, cardioprotective type of antiarrhythmic drugs. We have been working experimentally
using coronary occlusion/reperfusion induced ventricular ﬁbrillation. Na/H exchange
inhibitors have been proved to be eﬀective in eliminating coronary occlusion/reperfusion
injury including VF, infarct size and myocardial stunning in various animal models. Despite
clear eﬀectiveness in animals, several clinical trials using these drugs in ischemia related
situations failed to demonstrate clinical eﬀectiveness. This is shocking for pharmacologists
like me who believe that animal models should work well to predict clinical usefulness.
Using similar models of animal cardiac ischemia, Na/Ca exchange inhibitors and statins
have also been shown to suppress VF. These upstream acting drugs which prevent cardiac
tissues from deteriorating to become substrates for proarrhythmias theoretically should be
beneﬁcial, and hopefully will be examined in the clinic for their actual eﬀectiveness while
taking into consideration cost. I still believe that antiarrhythmic drugs have a place in
preventing premature death due to arrhythmias and that they will bring us an age where we
can beneﬁt from a ‘‘good sudden cardiac death’’.
Keitaro Hashimoto
Professor Emeritus, University of Yamanashi
131
